Jul 21, 2024, 11:23
Commercial interests appear to be influencing evidence standards for multi-cancer early detection tests
Dario Trapani, Medical Oncologist at European Institute of Oncology, shared a post by Benjamin Mazer, Assistant Professor of Pathology at Johns Hopkins University, on X:
“Commercials determinants of health are now being investigated and tacked based on a systematic strategy.
Cancer screening is now a big part of this problem.
See the recent WHO/Europe report from the NCD to learn more. ”
Quoting Benjamin Mazer‘s post:
“Commercial interests appear to be influencing evidence standards for multi-cancer early detection tests.”
Multicancer Early Detection Tests — Keeping a High Bar for Evidence of Benefit | NEJM
Authors: Hilary A. Robbins
Source: Dario Trapani/X and Benjamin Mazer/X
Aug 17, 2024, 15:47